Metis TechBio Co., Ltd. (METIS TECHBIO-P) disclosed its Monthly Return for Equity Issuer for June 2026, highlighting a notable enlargement of its Hong Kong–listed H-share capital driven by the full exercise of the over-allotment option related to its recent listing.

Key Developments 1. H-Share Issuance: • On 10 June 2026, 30.18 million new H shares were issued at HKD 10.50 each pursuant to the complete exercise of the over-allotment option. • This lifted the company’s issued H-share count by 2.87%, from 1,052.93 million to 1,083.11 million shares.

2. Authorised Share Capital: • Authorised H-shares increased by the same 30.18 million shares to 1,083.11 million, raising the H-share portion of authorised capital by RMB 3.02 million to RMB 108.31 million. • Domestic unlisted authorised shares remained unchanged at 99.59 million. • Aggregate authorised share capital across all classes closed the month at RMB 118.27 million.

3. Total Issued Shares: • Combined issued share capital (H-shares plus domestic unlisted shares) reached 1.18 billion shares as at 30 June 2026, up from 1.15 billion a month earlier.

4. Share Options: • The Pre-IPO Share Option Scheme maintained 18.39 million outstanding options; no options were exercised or lapsed during the month, leaving the potential dilutive impact unchanged.

5. Public Float: • Metis TechBio confirmed compliance with the Hong Kong Stock Exchange’s minimum 15% public-float requirement as of 30 June 2026.

Governance The monthly return was submitted on 6 July 2026 and signed by Chairman, Executive Director and CEO Tsai-Ta Lai.